Jump to content

PRX-07034: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
Importing Wikidata short description: "Chemical compound"
 
(23 intermediate revisions by 21 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Drugbox
{{Drugbox
| verifiedrevid = 424987327
| IUPAC_name = ''N''-[1-(5-chloro-2,3-dimethoxyphenyl)ethyl]-2-methylsulfonyl-5-piperazin-1-ylaniline
| IUPAC_name = ''N''-[1-(5-chloro-2,3-dimethoxyphenyl)ethyl]-2-methylsulfonyl-5-piperazin-1-ylaniline
| image = PRX-07034_structure.png
| image = PRX-07034.svg
| CAS_number = ?

⚫
| ATC_prefix = none
<!--Clinical data-->
| ATC_suffix =
| tradename =
⚫
| PubChem = 11532574
⚫
| legal_status = Uncontrolled
⚫
| C = 21 | H = 29 | Cl = 2 | N = 3 | O = 4 | S = 1
| molecular_weight = 490.44 g/mol
⚫
| smiles = COc2cc(Cl)cc(c2OC)C(C)Nc1cc(ccc1S(=O)(=O)C)N3CCNCC3
| bioavailability =
| metabolism =
| elimination_half-life =
| excretion =
| pregnancy_category =
⚫
| legal_status = Uncontrolled
| routes_of_administration = Oral
| routes_of_administration = Oral

<!--Identifiers-->
| CAS_number = 903580-16-5
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = YJ5TMF911R
⚫
| ATC_prefix = none
⚫
| PubChem = 11532574
| ChemSpiderID = 9707357

<!--Chemical data-->
⚫
| C=21 | H=29 | Cl=2 | N=3 | O=4 | S=1
⚫
| smiles = COc2cc(Cl)cc(c2OC)C(C)Nc1cc(ccc1S(=O)(=O)C)N3CCNCC3
| StdInChI = 1S/C21H28ClN3O4S/c1-14(17-11-15(22)12-19(28-2)21(17)29-3)24-18-13-16(25-9-7-23-8-10-25)5-6-20(18)30(4,26)27/h5-6,11-14,23-24H,7-10H2,1-4H3
| StdInChIKey = BSLXKMCHXRCBIH-UHFFFAOYSA-N

}}
}}


'''PRX-07034''' is a [[binding selectivity|selective]] [[5-HT6 receptor|5-HT<sub>6</sub> receptor]] [[receptor antagonist|antagonist]].<ref name="urlScience Links Japan | PRX-07034, a Potent and Selective 5-HT6 Receptor Antagonist, Reduces Food Intake and Body Weight in Rats">{{cite web | url = http://sciencelinks.jp/j-east/article/200617/000020061706A0577975.php | title = Science Links Japan &#124; PRX-07034, a Potent and Selective 5-HT6 Receptor Antagonist, Reduces Food Intake and Body Weight in Rats | format = | work = | accessdate = }}</ref> It has [[cognition]] and [[memory]]-enhancing properties and potently decreases [[food intake]] and [[body weight]] in rodents.<ref name="urlScience Links Japan | PRX-07034, a Potent and Selective 5-HT6 Receptor Antagonist, Reduces Food Intake and Body Weight in Rats"/><ref name="pmid18655798">{{cite journal | author = Fone KC | title = An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function | journal = Neuropharmacology | volume = 55 | issue = 6 | pages = 1015–22 | year = 2008 | month = November | pmid = 18655798 | doi = 10.1016/j.neuropharm.2008.06.061 | url = http://linkinghub.elsevier.com/retrieve/pii/S0028-3908(08)00241-4}}</ref><ref name="urlScience Links Japan | Combination of sub-threshold doses of Aricept and PRX-07034, a novel 5-HT6 receptor antagonist, enhances Novel Object Discrimination (NOD) memory">{{cite web | url = http://sciencelinks.jp/j-east/article/200617/000020061706A0578001.php | title = Science Links Japan &#124; Combination of sub-threshold doses of Aricept and PRX-07034, a novel 5-HT6 receptor antagonist, enhances Novel Object Discrimination (NOD) memory | format = | work = | accessdate = }}</ref><ref name="pmid17209663">{{cite journal | author = Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE | title = Serotonergic drugs : effects on appetite expression and use for the treatment of obesity | journal = Drugs | volume = 67 | issue = 1 | pages = 27–55 | year = 2007 | pmid = 17209663 | doi = | url = http://content.wkhealth.com/linkback/openurl?issn=0012-6667&volume=67&issue=1&spage=27}}</ref> PRX-07034 was under development by [[EPIX Pharmaceuticals Inc|Epix Pharmaceuticals]] for the treatment of [[obesity]] and [[cognitive impairment]] associated with [[Alzheimer's disease]] and [[schizophrenia]] but upon the company collapsing due to lack of funds the compound was auctioned to another corporation.<ref name="urlPREDIX Pharmaceuticals (PRDX): Fourth Predix drug candidate enters clinical trials">{{cite web | url = http://investorshub.advfn.com/boards/read_msg.aspx?message_id=11491017 | title = PREDIX Pharmaceuticals (PRDX): Fourth Predix drug candidate enters clinical trials | format = | work = | accessdate = }}</ref><ref name="urlEpix Pharmaceuticals, Inc. Announces a Successful Auction Sale of Five Drug Program Intellectual Properties on September 30, 2009">{{cite web | url = http://blog.taragana.com/pr/epix-pharmaceuticals-inc-announces-a-successful-auction-sale-of-five-drug-program-intellectual-properties-on-september-30-2009-6816/ | title = Epix Pharmaceuticals, Inc. Announces a Successful Auction Sale of Five Drug Program Intellectual Properties on September 30, 2009 | format = | work = | accessdate = }}</ref><ref name="urlEpix Pharmaceuticals, Inc. Announces a Successful Auction Sale of Five Drug Program Intellectual Properties on September 30, 2009"/><ref name="urlEpix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction">{{cite web | url = http://blog.taragana.com/pr/epix-pharmaceuticals-inc-announces-prx-07034-therapeutics-cns-phase-2-will-be-part-of-the-intellectual-property-offered-for-sale-at-the-september-30-2009-auction-4809/ | title = Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction | format = | work = | accessdate = }}</ref>
'''PRX-07034''' is a [[binding selectivity|selective]] [[5-HT6 receptor|5-HT<sub>6</sub> receptor]] [[receptor antagonist|antagonist]].<ref name="urlScience Links Japan | PRX-07034, a Potent and Selective 5-HT6 Receptor Antagonist, Reduces Food Intake and Body Weight in Rats">{{cite web | url = http://sciencelinks.jp/j-east/article/200617/000020061706A0577975.php | title = Science Links Japan &#124; PRX-07034, a Potent and Selective 5-HT6 Receptor Antagonist, Reduces Food Intake and Body Weight in Rats }}</ref> It has [[cognition]] and [[memory]]-enhancing properties and potently decreases [[food intake]] and [[body weight]] in rodents.<ref name="urlScience Links Japan | PRX-07034, a Potent and Selective 5-HT6 Receptor Antagonist, Reduces Food Intake and Body Weight in Rats"/><ref name="pmid18655798">{{cite journal | author = Fone KC | title = An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function | journal = Neuropharmacology | volume = 55 | issue = 6 | pages = 1015–22 |date=November 2008 | pmid = 18655798 | doi = 10.1016/j.neuropharm.2008.06.061 | s2cid = 35522597 }}</ref><ref name="urlScience Links Japan | Combination of sub-threshold doses of Aricept and PRX-07034, a novel 5-HT6 receptor antagonist, enhances Novel Object Discrimination (NOD) memory">{{cite web | url = http://sciencelinks.jp/j-east/article/200617/000020061706A0578001.php | title = Science Links Japan &#124; Combination of sub-threshold doses of Aricept and PRX-07034, a novel 5-HT6 receptor antagonist, enhances Novel Object Discrimination (NOD) memory }}</ref><ref name="pmid17209663">{{cite journal | vauthors = Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE | title = Serotonergic drugs : effects on appetite expression and use for the treatment of obesity | journal = Drugs | volume = 67 | issue = 1 | pages = 27–55 | year = 2007 | pmid = 17209663 | doi = 10.2165/00003495-200767010-00004 | s2cid = 46972692 | url = https://dx.doi.org/10.2165%2F00003495-200767010-00004 | access-date = 2010-03-09 | archive-url = https://archive.today/20130105064850/http://content.wkhealth.com/linkback/openurl?issn=0012-6667&volume=67&issue=1&spage=27 | archive-date = 2013-01-05 | url-status = dead }}</ref> PRX-07034 was under development by [[Epix Pharmaceuticals]] for the treatment of [[obesity]] and [[cognitive impairment]] associated with [[Alzheimer's disease]] and [[schizophrenia]] but upon the company collapsing due to lack of funds the compound was auctioned to another corporation.<ref name="urlPREDIX Pharmaceuticals (PRDX): Fourth Predix drug candidate enters clinical trials">{{cite web | url = http://investorshub.advfn.com/boards/read_msg.aspx?message_id=11491017 | title = PREDIX Pharmaceuticals (PRDX): Fourth Predix drug candidate enters clinical trials }}</ref><ref name="urlEpix Pharmaceuticals, Inc. Announces a Successful Auction Sale of Five Drug Program Intellectual Properties on September 30, 2009">{{cite web | url = http://pr.gaeatimes.com/epix-pharmaceuticals-inc-announces-a-successful-auction-sale-of-five-drug-program-intellectual-properties-on-september-30-2009-6816/ | title = Epix Pharmaceuticals, Inc. Announces a Successful Auction Sale of Five Drug Program Intellectual Properties on September 30, 2009 }}</ref><ref name="urlEpix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction">{{cite web | url = http://pr.gaeatimes.com/epix-pharmaceuticals-inc-announces-prx-07034-therapeutics-cns-phase-2-will-be-part-of-the-intellectual-property-offered-for-sale-at-the-september-30-2009-auction-4809/ | title = Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction }}</ref>


== References ==
== References ==
Line 29: Line 37:
{{Anorectics}}
{{Anorectics}}
{{Antidementia}}
{{Antidementia}}

{{Nootropics}}
{{Serotonergics}}
{{Serotonergics}}


{{DEFAULTSORT:Prx-07034}}
{{DEFAULTSORT:Prx-07034}}
[[Category:Piperazines]]
[[Category:Phenylpiperazines]]
[[Category:Anilines]]
[[Category:Anilines]]
[[Category:Phenol ethers]]
[[Category:Phenol ethers]]
[[Category:Organochlorides]]
[[Category:Chloroarenes]]

Latest revision as of 09:25, 16 October 2022

PRX-07034
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • N-[1-(5-chloro-2,3-dimethoxyphenyl)ethyl]-2-methylsulfonyl-5-piperazin-1-ylaniline
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H29Cl2N3O4S
Molar mass490.44 g·mol−1
3D model (JSmol)
  • COc2cc(Cl)cc(c2OC)C(C)Nc1cc(ccc1S(=O)(=O)C)N3CCNCC3
  • InChI=1S/C21H28ClN3O4S/c1-14(17-11-15(22)12-19(28-2)21(17)29-3)24-18-13-16(25-9-7-23-8-10-25)5-6-20(18)30(4,26)27/h5-6,11-14,23-24H,7-10H2,1-4H3
  • Key:BSLXKMCHXRCBIH-UHFFFAOYSA-N
  (verify)

PRX-07034 is a selective 5-HT6 receptor antagonist.[1] It has cognition and memory-enhancing properties and potently decreases food intake and body weight in rodents.[1][2][3][4] PRX-07034 was under development by Epix Pharmaceuticals for the treatment of obesity and cognitive impairment associated with Alzheimer's disease and schizophrenia but upon the company collapsing due to lack of funds the compound was auctioned to another corporation.[5][6][7]

References

[edit]
  1. ^ a b "Science Links Japan | PRX-07034, a Potent and Selective 5-HT6 Receptor Antagonist, Reduces Food Intake and Body Weight in Rats".
  2. ^ Fone KC (November 2008). "An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function". Neuropharmacology. 55 (6): 1015–22. doi:10.1016/j.neuropharm.2008.06.061. PMID 18655798. S2CID 35522597.
  3. ^ Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE (2007). "Serotonergic drugs : effects on appetite expression and use for the treatment of obesity". Drugs. 67 (1): 27–55. doi:10.2165/00003495-200767010-00004. PMID 17209663. S2CID 46972692. Archived from the original on 2013-01-05. Retrieved 2010-03-09.
  4. ^ "PREDIX Pharmaceuticals (PRDX): Fourth Predix drug candidate enters clinical trials".
  5. ^ "Epix Pharmaceuticals, Inc. Announces a Successful Auction Sale of Five Drug Program Intellectual Properties on September 30, 2009".
  6. ^ "Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction".
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=PRX-07034&oldid=1116389478"